News
Sanofi pays $180m for rights to Kali autoimmune drug
Sanofi has licensed rights to Kali's trispecific T-cell engager KT501, in trials for rheumatoid arthritis, in a deal valued at nearly $1.2bn.
News
Pfizer, Valneva shrug off phase 3 Lyme disease vaccine miss
Missing the primary endpoint in a phase 3 trial will not stop Pfizer from submitting Valneva-partnered Lyme disease vaccine for approval.
News
Dizal breaks new ground for EGFR drugs in lung cancer
Dizal's Zegfrovy has taken the oral EGFR inhibitor class into new territory, with a phase 3 win as a frontline treatment for a form of lung cancer.
News
Earendil raises $787m as lead TL1A antibody starts phase 2
Earendil has raised an impressive $787m in financing for its AI-powered drug platform, attracting yet more buy-in from Sanofi.
R&D
Longevity is not a consumer trend, but a pipeline strategy p...
Longevity is being framed as a consumer movement when, in reality, it is a pharmaceutical pipeline challenge.
Debates & Insights
News
Press Releases
Editor's Picks
Editor's Picks
